Cardiorenal Syndrome in Acute Heart Failure Syndromes by Sarraf, Mohammad & Schrier, Robert W.
SAGE-HindawiAccess to Research
International Journal of Nephrology
Volume 2011, Article ID 293938, 10 pages
doi:10.4061/2011/293938
Research Article
Cardiorenal Syndrome in Acute Heart Failure Syndromes
Mohammad Sarraf1 and RobertW. Schrier2
1University of Minnesota, USA
2University of Colorado, USA
Correspondence should be addressed to Robert W. Schrier, robert.schrier@ucdenver.edu
Received 22 November 2010; Accepted 9 January 2011
Academic Editor: Alejandro Mart´ ın-Malo
Copyright © 2011 M. Sarraf and R. W. Schrier. This is an open access article distributed under the Creative CommonsAttribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Impaired cardiac function leads to activation of the neurohumoral axis, sodium and water retention, congestion and ultimately
impaired kidney function. This sequence of events has been termed the Cardiorenal Syndrome. This is diﬀerent from the
increase in cardiovascular complications which occur with primary kidney disease, that is, the so-called Renocardiac Syndrome.
The present review discusses the pathogenesis of the Cardiorenal Syndrome followed by the beneﬁts and potential deleterious
eﬀects of pharmacological agents that have been used in this setting. The agents discussed are diuretics, aquaretics, natriuretic
peptides, vasodilators, inotropes and adenosine α1 receptor antagonists. The potential role of ultraﬁltration is also brieﬂy
discussed.
1.Introduction
Patients with acute heart failure syndromes (AHFS) are
usually admitted because of severe systemic congestion that
frequently presents with dyspnea. Known as the hallmark
of AHFS, congestion is mainly due to pulmonary venous
hypertension (World Health Organization type 2). These
patients may also present with low cardiac output and/or
systemichypotension.This hasrangedfrom<2%[1]to7.7%
[2] to 29% [3] depending on the series. Dyspnea is the most
common symptom in these patients that implies an elevated
pulmonary venous pressure that is often accompanied by
increased central venous pressure (CVP) and/or peripheral
edema. Therefore, the most reasonable therapeutic target
is systemic congestion. There is substantial evidence that
the main driver of morbidity, mortality, and readmission
to the hospital is volume overload [1–5]. Moreover, it is
well established that patients who are admitted with AHFS
and renal dysfunction have worse outcomes [1, 5–9]. In
this paper, we discuss the pathophysiology of AHFS and its
contribution to impairment of kidney function. In the end,
we approach the current evidenceof therapeuticstrategies in
patients with cardiorenal syndrome in AHFS.
2.Pathophysiology
As noted above, the hallmark of AHFS is congestion. The
interaction between the heart and the kidney is modulated
by the cardiorenal axis. The sympathetic nervous system
(SNS), renin-angiotensin-aldosterone system (RAAS), and
arginine vasopressin (AVP) are the primary neurohormones
that maintain the integrity of eﬀectivearterial blood volume,
hence the cardiorenal axis [4, 10–14].
In a nonfailing heart, an increase in left atrial pressure
stimulates a feedback system, which decreases the release
of AVP from posterior pituitary. This reﬂex is abolished
by vagotomy. Furthermore, the elevated atrial pressure
decreases the renal SNS stimulation. On the other hand,
natriuretic peptides are released due to myocardial stretch
and dilatation. The interaction of these pathways ultimately
increases sodium and water excretion thatmaintains a steady
state for totalblood volumeand preserves theintegrity ofthe
arterial circulation [4, 13]( F i g u r e1).
When heart failure develops, this physiologic response is
disrupted and the kidneys continue to retain sodium and
water despite an elevated total blood volume. However, the
primary regulation of body ﬂuid homeostasis is modulated2 International Journal of Nephrology
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Figure 1: Physiologic interaction of neurohormones and main-
tenance of total blood volume. U/O: Urine output, ↑:i n c r e a s e d ,
RAP: right atrial pressure, ANP: atrial natriuretic peptide, SNS:
sympathetic nervous system and AVP: arginine vasopressin.
by the smaller arterial circulation, enabling the system
responsible for the perfusion of the body’s vital organs to
respond to small changes in body ﬂuid volume [4, 10, 11].
This portion of blood volume only comprises 15% of the
total blood volume [10, 11]. Therefore, in a failing heart,
despite elevated total sodium and total water and signiﬁcant
engorgement of the venous system, kidneys continue to
retain sodium and water due to disrupted maintenance of
body ﬂuid homeostasis (Figure 2). This applies to patients
with low or high cardiac output [10].
Elevated level of renin secretion is demonstrated in early
stages of heart failure [14]. Renin stimulates angiotensin
II (Ang-II) generation. Angiotensin II causes arterial vaso-
constriction and therefore, increases cardiac afterload with
a resultant decrease in stroke volume. Moreover, Ang-II
stimulates the release of aldosterone and SNS.The activation
of RAAS and SNS results in further vasoconstriction of the
aﬀerent arterioles of the kidneys [4, 13] that decreases renal
blood ﬂow and glomerular ﬁltration rate (GFR). The stim-
ulation of RAAS and SNS also increases proximal tubular
absorption of sodium and decreases sodium delivery to the
distal tubules and collecting ducts, which is the site of action
of aldosterone [15]. Therefore, in patients with heart failure
escape from the sodium-retaining eﬀect of aldosterone on
the distal nephrons, a phenomenon that normally occurs, is
impaired. The end-result of this combined neurohormonal
activation is continuous reabsorption of sodium and water
which leads to congestion.
SNS is activated through increased Ang-II (see above)
as well as activation of the baroreceptors in the aorta and
aortic arch [11]. SNS has a positive feedback on RAAS
stimulationthatresultsin furtherstimulationofaldosterone.
Aldosterone and Ang-II both accelerate ﬁbrosis of the
myocardium and remodeling of the failing heart [16]. Fur-
thermore, neurohormones are strong mediators of oxidative
injury, inﬂammation, and cell death that leads to widespread
endothelial dysfunction. Thus, Ang-II exerts many deleteri-
ous eﬀects through the activation of NADPH- and NADH-
oxidase. These enzymes are activated within vascular smooth
muscle cells, cardiac myocytes, and renal tubular epithelial
cells, generating superoxide, a reactive oxygen species with
unfavorable eﬀects [17]. More importantly, nitric oxide
release by endothelium may be disturbed in the presence
of superoxide and reactive oxygen species. This results in
endothelial dysfunction, hypertension, and increased cardiac
afterload [17]. As many as 50% of patients with AHFS
present with a systolic blood pressure >140mm/Hg [1].
Elevated blood pressure is present in patients either with
systolic heart failure or heart failure with preserved ejection
fraction [1].
AVP is a hormone that is secreted from the posterior
pituitary and is normally suppressed by hypoosmolality. In
the failing heart, however, even in the presence of hypona-
tremia, and thus hypoosmolality, there is a marked increase
in AVP secretion secondary to nonosmotic baroreceptor-
mediated release of the hormone. This phenomenon com-
monly overrides the osmotic release of AVP [18–20]. AVP
activates the V2 receptor on the basolateral surface of
principal cell of the collecting duct.This increases expression
and traﬃcking of the aquaporin 2 water channel to the
apical surface. The resultant increased water permeability
of the collecting duct allows osmotic water equilibrium
with the hypertonic interstitium and urinary concentration.
Also, AVP stimulates the V1a receptors of the vascular
smooth muscle that results in vasoconstriction of the arterial
and venous system. Therefore, AVP increases preload and
afterload through V2 and V1a receptor activation [4]. Thus,
AVP potentially may result in further remodeling of the
myocardium by these pathways (Figure 3).
3.Goal of Therapy
It is evident that the neurohormonal storm and worsen-
ing kidney function in AHFS ultimately ensue to venous
congestion and elevated central venous pressure (CVP),
which results in a vicious cycle. In a prospective cohort
of 145 patients from the Cleveland Clinic, CVP was the
most important hemodynamic factor causing worsening
renal function in patients with AHFS [21]. In addition, in
a retrospective analysis of 2557 patients who underwent
cardiac catheterization for hemodynamic assessment, ele-
vatedCVPremained asthesingle mostimportant prognostic
factorforworsening renalfunctionandmortality[22].There
is growing evidence that hypervolemia, that is, increased
pulmonary capillary wedge pressure, independently corre-
lates with mortality [23] and may predict an urgent need
for cardiac transplantation [24]. Furthermore, improvement
in cardiac output/index in patients with AHFS has little
impact on outcome of patients with AHFS [25], even when
therapy for decongestion is modulated carefully by invasive
hemodynamic assessment [26]. Furthermore, transmission
of venous pressure to renal venous system impairs renal
blood ﬂow and GFR. In 1861, Ludwig observed that as
CVP increased above 10mm/Hg, the urine output started
to fall [27]. In 1931, Winton showed in isolated kidneys
from dogs, that elevated venous pressure drops the urine
output, while the arterial side was connected to a perfusingInternational Journal of Nephrology 3
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Figure 2: Pathophysiology of acute decompensated heart failure. (Reproduced with permission from [8].)
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Figure 3: Vasopressin stimulation of V2 and V1a receptors can contribute to events that worsen cardiac function (with permission from
[2].)
pump [28]. More recently, Mullens et al. demonstrated that
intra-abdominal pressure (IAP) correlated with worsening
renal function and lowering IAP improves renal function
[29]. Thus, the focus of the clinician should be on reducing
the congestion with as little hemodynamic compromise as
possible. The rate of ﬂuid removal, therefore, should not
exceed the interstitial ﬂuid mobilization rate (estimated at 12
t o1 5m L / m i n ) ,s i n c ei tm a yf u r t h e ra c t i v a t et h eR A A Sa n d
worsen the neurohormonal storm [25, 30].
4.TreatmentofPatientswithAHFS
Much of the challenge of the management of patients
with cardiorenal syndrome who present with AHFS lies in
the balance of decongestion and hemodynamic compro-
mise. Ideally, one wishes to lower the preload, afterload
and pulmonary capillary wedge pressure without reduc-
ing the blood pressure and GFR. Thus, the ideal agent
should reduce left ventricular ﬁlling pressure, pulmonary4 International Journal of Nephrology
Table 1: Pharmacologicagents in the managementof patients with AHFS.
Medication Initial dose Dose range comments
Diuretics
Furosemide 20–80mg IV bolus 20–400mg boluses may
repeat q6–8H
Infusion is recommended at 5 to 40mg/hr. If >240mg/hr,
risk of ototoxicity increases
Torsemide 10–40mg bolus 20–200mg bolus Continuous infusion:5–20mg/hr
Bumetanide 0.5–2mg bolus 0.5–4mg bolus Continuous infusion: 0.1–0.5mg/hr
Vasodilators
Nitroprusside 0.3–0.5μg/kg/min 0.3–5μg/kg/min Infusion rates of >10μg/kg/min may cause cyanide
toxicity. Also, caution during active myocardial ischemia
Nitroglycerine 10–20μg/min 20–400μg/min severe headache, hypotension, closed-angle glaucoma
Nesiritide NO BOLUS 0.005–0.03μg/kg/min
Titration: increase infusion rate by 0.005μg/kg/min (no
more than every 3hr, up to a maximum of
0.03μg/kg/min)
Inotropes
Dopamine 2–5μg/kg/min 2–20μg/kg/min May increase mortality. Caution for arrhythmia
Dobutamine 1-2μg/kg/min 1–20μg/kg/min May increase mortality. Caution for arrhythmia
Milrinone
50μg/kg IV loading dose
over 10min; then
0.25–1.0μg/kg/min infusion
0.10–0.75μg/kg/min May increase mortality. Caution for arrhythmia
Other
Levosimendan
0.05–0.2μg/kg/min bolus
over 10min followed by
infusion
0.5–2.0μg/kg/min May increase mortality. Not approved in the US. Caution
for hepatic impairment and LV outﬂow obstruction
congestion, improve renal function, preserve myocardial
tissue, reduce neurohormonal levels, and not increase the
incidence of arrhythmias. Unfortunately, to date there is
no such medical regimen available. Since congestion is the
hallmark of heart failure and correlates with morbidity and
mortality in short, and long-term studies (see above), the
primary aim of therapy should focus on decongestion with
the goals described above.
5. Pharmacologic Approach
We divide therapy to pharmacologic and nonpharmacologic
interventions with the latest available evidence. For phar-
macologic approach, one may utilize diuretics, aquaretics
(V2 receptor antagonists), vasodilators, and inotropes. For
nonpharmacologic approach, there is a paucity of well-
done randomized control data in patients with AHFS;
nevertheless, we will discuss the role of ultraﬁltration in
patients with AHFS.
5.1. Diuretics. Heart Failure Society of America guidelines
recommends loop diuretics as the corner stone of ther-
apy in patients with congestive symptoms in the setting
of AHFS [31]. More than 88% of patients receive loop
diuretics,mainly intravenously[1].Therearenorandomized
controlled trials to have evaluated the outcome studies of
loop diuretics, but it is evident that patients with AHFS
should not be left in the congestive state. As stated earlier,
congestion correlates with mortality. Loop diuretics relieve
the symptoms, even before diuresis [31] and also reduce
the wedge pressure and left ventricular ﬁlling pressure. In
patients who have severe congestion and renal dysfunction,
diuresis may improve kidney function, possibly through
relieving the venous and/or abdominal congestion. The
dilemma, however,isthe fact thatthereisno prognostication
as to which patient will improve or worsen with diuretic
therapy. In Table 1 are listed the diuretics in clinical practice
for AHFS.
Comprehensive HFSA guideline recommends switching
from intravenous to continuous infusion in patients who
seem to be nonresponsive to diuretics [31]. This question
has been recently investigated in a randomized double-blind,
double dummy controlled trial in a 2 × 2 factorial design
in Diuretic Optimization Strategies Evaluation (DOSE) trial
[30]. In this study, the investigator concluded there was no
statistically signiﬁcant diﬀerence in global symptom relief or
change in renal function at 72 hours (coprimary endpoint)
between intermittent versus continuousinfusion or low dose
(×1 oftheoral outpatientdose)versushigh dose(×2.5times
oftheoraloutpatientdose)[32].This istheﬁrstrandomized,
controlled exploration of a management strategy in loop
diuretics in AHFS patients. However, the high-dose strategy
caused a mild renal dysfunction that was reversible withinInternational Journal of Nephrology 5
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Figure 4: The mechanisms of adverse eﬀects of loop diuretics (with permission from [11]).
one week. There was also no evidence for increased risk of
clinicaleventsat 60daysafter high-dose therapyor after low-
dose, continuous, or intermittent diuretic therapy. On the
other hand, patients in the high-dose group, compared with
the low-dose group, showed signiﬁcant improvements in a
series ofsecondary endpointsassessed at 72hours, including
weight loss, heart-failure biomarkers and dyspnea [32].
Despite all the beneﬁts of loop diuretics in acute
setting there are serious adverse eﬀects associated with
these agents [13]. Loop diuretics frequently develop elec-
trolyte abnormalities, mainly hyponatremia, hypokalemia
and hypomagnesemia. The loop diuretics inhibit the mac-
ula densa of the nephron. This results in further release
of renin and stimulation of neurohormones and acute
vasoconstriction response after administering loop diuretics
(Figure 4)[ 33]. The vasoconstriction can reduce the GFR by
further aﬀerent vasoconstriction, which may occur despite
substantialincreaseinurineoutput[34].However,improved
myocardial function may develop due to reduction in
ventricular size and wall stress. This may ultimately diminish
mitral regurgitation and improve cardiac output and GFR
[13]. Hypotension does not frequently happen when using
diuretics, but it may occur in the presence of generous doses
of vasodilators.
Another important dilemma in managing these patients
is diuretic resistance. Patients with AHFS have signiﬁcant
neurohormonal activation and may have chronic kidney
dysfunction [1]. Using loop diuretics may quickly worsen
the compromised GFR and further enhance neurohormonal
stimulation. In addition, there is a potential hypertrophy
of the distal tubule in these patients that further limits
the kidney’s response to diuretics [35, 36]. To overcome
diuretic resistance, it is always a reasonable approach to limit
total daily sodium intake to less than 2gm. HFSA guideline
recommends ﬂuid restriction of 2 liters and if patient
has moderate hyponatremia (<130mEq/L), more aggressive
ﬂuid restriction [31]. The pharmacologic approach to over-
come resistance is to add another diuretic that blocks the
distal tubule, such as a thiazide diuretic. Another approach
is adding metolazone but consideration of the agent’s long
half life is very important (∼5 days). Lastly, switching from
intermittent to continuous infusion may be considered,
although as stated above, in the randomized control study,
the outcome was not diﬀerent. At the time of writing of this
paper further details of the DOSE trial are not available.
5.1.1. Mineralocorticoid Antagonists. About 50% of patients
withAHFShaveheartfailurewithpreservedejectionfraction
(HFPEF) [1]. In these patients, the neurohormonal stimula-
tion is independent of the cardiac outputor ejection fraction
of the patient. On the other hand, cirrhotic patients share a
commonpathophysiologyforsodiumandwaterretentionby
neurohormonal activation secondary to splanchnic vasodi-
lation. As stated earlier, patients with heart failure cannot
escape from the sodium-retaining eﬀect of aldosterone.
The same is true for cirrhotic patients with ascites. Thus,
patients with heart failure have a similar pathophysiology of
cirrhotic patients. Both patient populations have secondary
hyperaldosteronism. The diuretic of choice in cirrhosis is
mineralocorticoid antagonists, not a loop diuretic[37].They
are used as the mainstay of therapy since they target a
primary underlying pathophysiology of the disease namely,
secondary hyperaldosteronism. Loop diuretics are utilized
in cirrhosis as an adjunct. In the Randomized Aldactone
EvaluationStudy(RALES),spironolactonewasusedas25mg
orally once a day [38]. It was shown that this dose did not
decrease sodium retention. The interpretation of the RALES6 International Journal of Nephrology
study therefore was that the results were due to nongenomic,
nonnatriuretic eﬀects of spironolactone on myocardium
by preventing further remodeling and/or reducing ﬁbrosis
[38]. There are limited data for using the natriuretic doses
of spironolactone (at least 50mg orally once a day) in
patients with heart failure. To our knowledge, other than
a small report, there are no randomized well-conducted
studies available to evaluate the eﬀect of natriuretic doses of
spironolactone in heart failure patients. In 1965, Braunwald
et al. conducted a small trial of spironolactone in 3 patients
with heart failure (mainly due to valvular disease). The dose
of spironolactone utilized in that study was 100mg orally
once a day and sodium excretion increased [39]. In a small
prospective study in patients with severe heart failure and
conﬁrmed diuretic resistance, the eﬀect of spironolactone
was investigated [38]. All medications were discontinued.
Spironolactone was started at 200mg orally twice a day,
while the patients were taken oﬀ supplemental potassium.
Over a 4-day period, spironolactone completely abolished
the urinary sodium retention and atrial natriuretic peptide
diminished substantially [40].
Since the publication of RALES study, there has been
some concern regarding the risk of hyperkalemia. This
cautionary note is mainly based on one epidemiologic study
from Canada. In this study, the investigators observed a
statistically signiﬁcant increased risk of hospitalization and
hospital mortality in association with hyperkalemia after
publication of the RALES trial [41]. However, a subanal-
ysis of Eplerenone Post-Acute Myocardial Infarction Heart
Failure Eﬃcacy and Survival Study (EPHESUS) showed that
eplerenone (dose range of 25 to 50mg/d) in postmyocardial
infarction patients with heart failure and/or LV ejection
fraction (LVEF < 40%) did not signiﬁcantly increase the
risk of hyperkalemia [42]. Furthermore, in another study
from Scotland, in a population-based longitudinal analysis
in patients with or without heart failure, there has been
no increase in hospitalizations for hyperkalemia between
1994 to 2007 [43]. Nevertheless, with the paucity of results
with natriuretic doses of mineralocorticoid antagonists
(>25mg/day of spironolactone or >50mg of eplerenone),
prospective, randomized studies need to be performed in
patients with AHFS, in the presence of a low-potassium
diet and a potassium-losing loop diuretic, to block the
sodium retaining eﬀect of aldosterone by careful titrating of
spironolactone doses greater than 25mg/d. If shown to be
eﬀective in treating congestion in AHFS, this could alter the
frequent rehospitalization for congestion and the discharge
of AHFS patients with continued symptoms of congestion
(estimated to be ∼50%).
5.2. Vasopressin Antagonists (Aquaretics). The only phar-
macologic agent other than loop diuretics that is capable
of rapid diuresis in AHFS is vasopressin antagonist. V2
receptors are stimulated by AVP and increase the aquaporins
(seeabove)onthedistalnephronsandincreasespermeability
to water. A profound water diuresis (aquaresis) occurs by
blocking the V2 receptors. Unlike any other diuretics, V2
antagonistsdonotaﬀecttheurinary excretion ofelectrolytes.
In fact, in patients with hyponatremia, the serum sodium
concentration normalizes while the intravascular volume is
decreasing. Currently, there are 2 vasopressin antagonists
available in the U.S., conivaptan and tolvaptan. Conivaptan
is a mixed antagonist (V1a and V2 antagonist) and tolvaptan
is a selective V2 receptor antagonist. The indication for use
for both agents is the presence of hyponatremia and heart
failure. It is not indicated for hypervolemia in the absence of
hyponatremia [44].
In the Acute and Chronic Therapeutic Impact of a
Vasopressin antagonist in Congestive Heart Failure (ACTIV)
trial, 319 patients with heart failure were randomized in
3d i ﬀerent doses of tolvaptan [45]. Tolvaptan produced
a signiﬁcant decrease in body weight throughout hospi-
talization and a modest improvement in HF symptoms
without any adverse hemodynamic compromise, electrolytes
abnormalities, or renal dysfunction. A post-hoc analysis
of this study demonstrated that mortality was reduced in
patientswithrenal dysfunction orseveresystemiccongestion
in the tolvaptan arm [44]. In a followup study of the Eﬃcacy
of Vasopressin Antagonism in Heart Failure Outcome Study
With Tolvaptan (EVEREST) trial, patients were randomized
to tolvaptan or placebo and followed for short term and
long-term (median follow-up of 9.9 months) outcomes[46].
While tolvaptan produced a substantial normalization of the
serum sodium concentration and signiﬁcant weight loss in
comparison to placebo, these ﬁndings did not translate to
beneﬁcial eﬀect on readmission for heart failure or mortality
[46]. EVEREST did show a statistically signiﬁcant decrease
in dyspnea during the ﬁrst week on congestion. Thus far,
there is only one study in AHFS patients with a mixed
V1a/V2 antagonist (conivaptan) [47]. In this pilot study
with conivaptan, there was a marked aquaresis in heart
failurepatientswithoutanyhemodynamic compromise[47].
Whether this agent improves outcomes of patients with
AHFS remains to be elucidated.
5.3. Natriuretic Peptides. Brain natriuretic peptides (BNP)
act upon guanylyl cyclase-linked natriuretic peptide recep-
tors A and B. The downstream pathway of stimulation of
these receptors is increased cyclic GMP production. Natri-
uretic peptides reduce the cardiac ﬁlling pressure and can
improve symptoms of dyspnea as shown in Vasodilatation
in the Management of Acute CHF study (VMAC) [48].
Nesiritide, a synthetic natriuretic peptide, was able to reduce
signiﬁcantly the pulmonary capillary wedge pressure in 15
minutes when compared to placebo, butnot when compared
to nitroglycerine [48]. Subsequently, signiﬁcant concern was
raised against nesiritide by a meta-analysis of randomized
controlled trials that found a signiﬁcant increased risk of
worsening renal function [49]. In a retrospective study from
the Mayo Clinic, Riter et al. demonstrated if these agents
are judiciously used in low doses without an initial bolus
(as was the case in the trials), the renal function improves
[13,50].Thisapproachhasnotbeenstudiedinarandomized
controlled trial.
5.4. Vasodilators. Decongestion is the center focus of treat-
ment of patients with AHFS with the expectation that
as intravascular volume falls, cardiac ﬁlling pressures willInternational Journal of Nephrology 7
decline and symptoms improve. Therefore, it is a reasonable
approach to target the systemic vascular resistance. By
decreasing the vascular resistance, the cardiac ﬁlling pres-
sures, pulmonary and systemic congestion may be alleviated
and ventricular systolic and diastolic function may improve.
Nitroglycerine (NTG) improves the hemodynamics by
decreasing right atrial pressure, pulmonary capillary wedge
pressure, and reducing afterload [13]. These changes have
a substantial eﬀect on the congestive state of the patient.
Furthermore, by reducing the preload, the myocardial
stretch is diminished and the myocardial wall stress declines
substantially. While all of these changes intuitively make
therapeutic sense, there has never been any study in patients
with AHFSrandomized toNTGversusplacebo.There isonly
one study of comparison of high-dose NTG and low-dose
furosemide versus low-dose NTG and high-dose furosemide
in patients with AHFS that was in favor of high-dose NTG
and low-dose furosemide [51]. While NTG may decrease
BNP, there is a concern for renin elevation, most likely
due to hypotension [52]. There is ample evidence that
NTG increases coronary ﬂow, but whether the coronary
circulation changes in AHFS due to elevated LVEDP and
reduced coronary perfusion pressure are beneﬁcial is not
well studied. This is particularly important in heart failure
patients with ischemic cardiomyopathy. Judicious use of
NTGin appropriately selected patients seems to be quite safe
(Table 1).
Nitroprusside is a very potent balanced venous and
arterial vasodilator. It remains the reference vasodilator for
severe acute low-output left-sided heart failure as long as the
arterial pressure is reasonable. In patients with congestion
and acutemyocardial infarction, nitroprusside is the agentof
choice. In patients who present with acute or chronic heart
failure, it is still a very reasonable option, as long as the
clinicianisaware ofthepotentialsideeﬀectsofnitroprusside.
The most important side eﬀects is the precipitous fall in
blood pressure (that should be avoided in AHFS), possible
coronary steal, and thiocyanate toxicity, which can be fatal if
not treated promptly [15].
5.5. Inotropes. In extreme conditions when the cardiac
output is compromised, there is a clear indication for
using inotropes. Once very well received in intensive care
units, inotropes now are utilized less often except for
condition just described. There is substantial evidence in
largerandomizedclinicaltrialsaswellasretrospectivestudies
that these agents signiﬁcantly increase mortality despite all
the desirable eﬀects on hemodynamics including increasing
cardiac output and reducing systemic vascular resistance.
With the exception of dopamine none of the inotropes have
any eﬀects on renal hemodynamics.
Dobutamine is a synthetic catecholamine that acts on
β1 and weakly on β2 receptors. The β1 receptor has a
vasodilatory eﬀect on the vascular smooth muscle and
positive inotropy on the myocardium. So, by improving
the contraction of myocardium and reducing afterload the
cardiac output improves. Milrinone blocks the phosphodi-
esterase inhibitor III that ordinarily deactivates cyclic AMP
(cAMP). The increased cytosolic level of cAMP improves
the myocardial function and decreases the vascular tone
similartodobutamine,butbyadiﬀerentmechanism. Anovel
inotrope that is not approved by FDA in the US is levosi-
mendan. This agent stabilizes the conformational change
of troponin to calcium and increases contraction. There
was a randomized study with and without levosimendan in
patients with severe heart failure which demonstrated an
improvement in renal function with levosimendan [53].
Dobutaminehas improved the symptoms in heart failure
up to 30 days [54, 55]. In a large registry of patients with
AHFS, however, dobutamine was associated with a marked
increase in mortality when compared to NTG [56]. In the
Intravenous Milrinone for Exacerbations of Chronic Heart
Failure (OPTIME-CHF), 951 patients without cardiogenic
shock were randomized to milrinone versus placebo. The
main outcome of the study was the cumulative days of
hospitalization for cardiovascular cause within 60 days
following randomization. There was no statistically signif-
icant diﬀerence between the groups. There was a trend
towards higher mortality in milrinone group (P = .19).
Patients in milrinone arm had more episodes of hypotension
that required intervention compared to placebo [57]. In
the Randomized Multicenter Evaluation of Intravenous
Levosimendan Eﬃcacy (REVIVE) II study, the investigator
demonstrated a signiﬁcant symptomatic improvement of
33%in levosimendanarm [58].But,thisﬁnding wasnegated
byatrendtowardincreasedmortalityinpatientsrandomized
to levosimendan [59].
The routine use of inotropes, therefore, is not recom-
mended unless the patient’s hemodynamics are severely
compromised. It is evident that all inotropes may cause
harm, mainly by increased mortality. In the era of beta
blockade as one of the main treatments for chronic heart
failure, many patients may present with AHFS while they are
on beta blockers. There are no data as to whether it is safe
or unsafe to stop the beta blockade, but a recommendation
t od e c r e a s et h ed o s eb y5 0 %a n dc o n t i n u ew i t hi n o t r o p e
of choice seems reasonable. It is important to note that
among all inotropes, dobutamine and dopamine act upon
beta receptors. So, if it is possible to use milrinone that has
ad i ﬀerent mechanism of action and there is no need to
stop beta blockers unless the patient is in preshock or shock
state that prompts the physician to stop the beta blockers
immediately.
5.6. Adenosine α1 Receptor Antagonists. Adenosine is
markedly elevated in patients with AHFS. Since adenosine
has a profound vasoconstrictor eﬀect on the glomeruli,
it is theoretically attractive to hypothesize that blockade
of adenosine would improve the kidney function and
outcomes. Since adenosine acts upon α1 receptor on the
aﬀerent glomerulus, the agent of choice should be a selective
α1 adenosine receptor blocker. In the Placebo-Controlled
Randomized Study of the Selective A1 Adenosine Receptor
Antagonist Rolofylline for Patients Hospitalized with Acute
Decompensated Heart Failure and Volume Overload to
Assess Treatment Eﬀe c to nC o n g e s t i o na n dR e n a lF u n c t i o n
(PROTECT) a randomized, double-blind controlled
study with rolofylline failed to show any diﬀerence as8 International Journal of Nephrology
to the primary composite end point of persistent renal
impairment, hospital readmission, or death in up to 60 days
after admission [60].
5.7. Ultraﬁltration. Theoretically it is very reasonable to
approachtopatientswithAHFSwho present withsigniﬁcant
volume overload. Ultraﬁltration bypasses the kidney and
there is virtually no immediate neurohormonal stimula-
tion as occurs with loop diuretics blocking the macula
densa. In the Ultraﬁltration versus Intravenous Diuretics
for Patients Hospitalized for Acute Decompensated Heart
Failure (UNLOAD) trial, there was a marked decrease in
body weight, vasoactive drug requirement as well as hospital
readmission in 90 days in the ultraﬁltration arm [61].
However, this was associated with a trend towards higher-
serum creatinine level in the ﬁrst week of therapy in the
ultraﬁltration arm. One critiqueto this study may be the fact
that patients in the diuretic arm were not very aggressively
diuresed. So, it may be more diﬃcult to demonstrate such
beneﬁcial eﬀects if compared with diuretic therapy of com-
parable negative ﬂuid balance. Nonetheless, it is a reasonable
option in patients who are left in congestive state and make
littleurinedespitemaximalmedicaltherapy.Thereisarecent
study comparing the eﬀects of ultraﬁltration versus diuretics
in decompensated heart failure. Ultraﬁltration showed a
greater clinical and hemodynamic improvement, as well
as a decrease in aldosterone and N- terminal pro-B-type
natriuretic peptide [62].
6.Conclusion
Cardiorenal syndrome is frequently present in patients who
present with AHFS. The main driver of the pathophysiology
and symptomatology of the patients is congestion. The focus
of treatment should be relieving the congestion without
perturbing the hemodynamics of the cardiorenal axis. As
discussed in this paper, unfortunately every modality of
treatment has beneﬁcial and detrimental eﬀects on this axis.
Loop diuretics relieve congestion but stimulate the neuro-
hormonesandreduceGFR.Inotropesimprovehemodynam-
ics but can potentially increase mortality and arrhythmias.
Aquaretics have not been proven to decrease mortality in
a large randomized control trial, although there are no
large data on mixed receptor blockers. Natriuretic peptides
may worsen the kidney function and possibly increase
mortality. Vasodilators can cause substantial hypotension
while improving the hemodynamics. There is very little
data about the use of natriuretic doses of mineralocorticoid
receptorantagonistsinsevereheartfailure. Forthesereasons,
it is not possible to give one set of hard and fast rules to treat
the AHFS patients who present with cardiorenal syndrome.
This is left to the astute clinician to take advantage of every
agent at the appropriately selected patients.
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